AG
INKT icon

Artal Group’s MiNK Therapeutics INKT Stock Holding History

Artal Group’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-192
Closed -$1.74K – 125
2024
Q1 		$1.74K Hold
192
– – ﹤0.01% 111
2023
Q4 		$2K Hold
192
– – ﹤0.01% 96
2023
Q3 		$2K Sell
192
-22,630
-99% -$368K ﹤0.01% 103
2023
Q2 		$479K Sell
22,822
-6,137
-21% -$123K 0.01% 102
2023
Q1 		$549K Hold
28,959
– – 0.03% 102
2022
Q4 		$756K Hold
28,959
– – 0.04% 108
2022
Q3 		$611K Hold
28,959
– – 0.03% 123
2022
Q2 		$408K Hold
28,959
– – 0.02% 125
2022
Q1 		$652K Hold
28,959
– – 0.03% 130
2021
Q4 		$1.29M Buy
+28,959
New +$3.44M 0.04% 135

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artal Group's INKT Position: Q2 2024 in Review

Artal Group sold out of MiNK Therapeutics (INKT) in Q2 2024, closing a stake of 192 shares — an estimated $1.74K sold.

Artal Group first reported a position in INKT in Q4 2021 and held it in 10 quarters. The position peaked at $1.29M in Q4 2021. 29 funds tracked by Wall St. Rank hold INKT as of Q2 2024.

  • Artal Group reported no remaining MiNK Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Artal Group sold 192 MiNK Therapeutics shares in Q2 2024, an estimated $1.74K.
  • Artal Group first reported a position in MiNK Therapeutics in Q4 2021 and held it in 10 quarters.
  • Artal Group's MiNK Therapeutics position peaked at $1.29M in Q4 2021.
  • 29 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2024.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.